# EDGAR Filing Document

**Accession Number:** 0001167379
**File Stem:** 0001167379-26-000002
**Filing Date:** 2026-1
**Character Count:** 6720
**Document Hash:** 4fe8163425f211b7e82192499f21ccf6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001167379-26-000002.hdr.sgml**: 20260107

**ACCESSION NUMBER**: 0001167379-26-000002

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 7

**CONFORMED PERIOD OF REPORT**: 20260106

**FILED AS OF DATE**: 20260107

**DATE AS OF CHANGE**: 20260106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALCON INC
- **CENTRAL INDEX KEY:** 0001167379
- **STANDARD INDUSTRIAL CLASSIFICATION:** OPHTHALMIC GOODS [3851]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 980205094
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-31269
- **FILM NUMBER:** 26513647

**BUSINESS ADDRESS:**
- **STREET 1:** 6201 SOUTH FREEWAY
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76134
- **BUSINESS PHONE:** 817 293 0450

**MAIL ADDRESS:**
- **STREET 1:** CHEMIN DE BLANDONNET 8
- **STREET 2:** 1214 VERNIER
- **CITY:** GENEVA
- **STATE:** V8
- **ZIP:** 0000

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

_________________

**FORM 6-K** 

_________________

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**January 6, 2026**

**Commission File Number: 001-31269** 

_________________

**ALCON INC.** 

(Registrant Name)

**Rue Louis-d'Affry 6** <br>**1701, Fribourg, Switzerland** 

(Address of principal executive office)

_________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ &nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ☐

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 99.1 | <u>[Press release issued by Alcon Inc. dated January 6, 2026](alcon_staarxterminationxpr.htm)</u> |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **ALCON INC.** | **ALCON INC.** |
| Date: | January 6, 2026 | By: | /s/ Timothy C. Stonesifer |
|  |  | Name: Timothy C. Stonesifer | Name: Timothy C. Stonesifer |
|  |  | Title: Authorized Representative | Title: Authorized Representative |
| Date: | January 6, 2026 | By: | /s/ Thomas R. Hudnall |
|  |  | Name: Thomas R. Hudnall | Name: Thomas R. Hudnall |
|  |  | Title: Authorized Representative | Title: Authorized Representative |

---

## Exhibit 99.1

![image_4.jpg](image_4.jpg)![image_3.jpg](image_3.jpg)

**MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG**

**Alcon Terminates Agreement to Acquire STAAR Surgical** 

**Ad hoc announcement pursuant to Art. 53 LR**

**GENEVA (January 6, 2026) -** Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ: STAA) announced on August 5, 2025.

"Throughout this process we remained disciplined with our views on price and risk. Moving forward, our refractive strategy is unchanged and our new wavelight<sup>®</sup> plus offering remains our focus for the most popular refractive surgery in the world, LASIK. This will be an exciting year for Alcon as we continue the global launches of more than 10 major products in both our surgical and vision care franchises. These innovations substantively advance outcomes for eye care disorders and help patients around the world see brilliantly," said David J. Endicott, CEO of Alcon.

**<u>Cautionary Note Regarding Forward-Looking Statements</u>**

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "target," "assume," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release speak only as of the date they are made, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

**<u>About Alcon</u>**

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative

------

<br> <br> <br>

products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at <u>www.alcon.com</u>.

&nbsp;&nbsp;&nbsp;&nbsp;

**Connect with us on**

![image_0.jpg](image_0.jpg)![image_1.jpg](image_1.jpg)

**<u>Investor Relations</u>**

Daniel Cravens, Allen Trang

+ 41 589 112 110 (Geneva)

+ 1 817 615 2789 (Fort Worth)

<u>investor.relations@alcon.com</u>

**<u>Media Relations</u>**

Steven Smith

+ 41 589 112 111 (Geneva)

+ 1 817 551 8057 (Fort Worth)

<u>globalmedia.relations@alcon.com</u>

![image_2.jpg](image_2.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2/#NUM_PAGES#

------

<br> <br> <br>

<br>